Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | APOB | P04114 | 2/20 | 0.40 |
| ▸ | MTTP | P55157 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.39 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3292142 | 0.86 | MTTP (0.52) | APOBMTTPKMT2ASMN1; SMN2 | |
| SCHEMBL3290189 | 0.80 | SMN1; SMN2 (0.51) | APOBMTTPSMN1; SMN2 | |
| SCHEMBL3292088 | 0.80 | MTTP (0.48) | CHRM3APOBMTTPSMN1; SMN2 | |
| SCHEMBL5144167 | 0.80 | KDM4E (0.48) | EPHX2CHRM3APOBMTTPSMN1; SMN2 | |
| SCHEMBL13329128 | 0.79 | MTTP (0.50) | APOBMTTPSMN1; SMN2 | |
| SCHEMBL3288828 | 0.78 | MTTP (0.65) | APOBMTTP | |
| SCHEMBL4074915 | 0.77 | APOB (0.51) | EPHX2APOBMTTPSMN1; SMN2 | |
| SCHEMBL3290350 | 0.77 | KDM4E (0.50) | CHRM3APOBMTTPKMT2ASMN1; SMN2 | |
| SCHEMBL3289504 | 0.75 | GAA (0.60) | EPHX2KMT2ASMN1; SMN2 | |
| SCHEMBL5145537 | 0.75 | SMN1; SMN2 (0.52) | EPHX2CHRM3APOBMTTPSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723358-B2 | Aroyl-O-piperidine derivatives for the treatment of diabetes-related problems | MERCK PATENT GMBH (DE) | 2010-05-25 | — | — | US | disclosed |
| US-7723358-B2 | Aroyl-O-piperidine derivatives for the treatment of diabetes-related problems | MERCK PATENT GMBH (DE) | 2010-05-25 | — | — | US | disclosed |
| US-7723358-B2 | Aroyl-O-piperidine derivatives for the treatment of diabetes-related problems | MERCK PATENT GMBH (DE) | 2010-05-25 | — | — | US | disclosed |
| US-20070254919-A1 | Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems | MERCK PATENT GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
| US-20070254919-A1 | Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems | MERCK PATENT GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
| US-20070254919-A1 | Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems | MERCK PATENT GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254919-A1 | Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems | GPR119, FABP4, LIPC | LIPE 15/4885EPHX2 1594/4885CHRM3 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.